Shots:

• The US FDA has approved Eprontia (25mg/mL) oral solution as a monothx for partial-onset or primary generalized tonic-clonic seizures. The oral solution is also approved as an adjunctive treatment for the same indication or seizures associated with Lennox-Gastaut syndrome in patients aged ≥2yrs. along with treatment of migraine in patients aged ≥12 yrs.
• Azurity will lead the commercialization of the product & is expected to be available at the end of 2021
• Eprontia is the 1st oral liquid formulation of topiramate to be approved by the US FDA. Eton will receive a $5M milestone upon the commercial launch of Eprontia & is eligible to receive commercial milestones along with royalties

Ref: Globe Newswire | Image: Eton